🔗 Share this article

Elected officials have expressed alarm that the United Kingdom's recent agreements with the US administration are "lacking a solid foundation." This follows revelations that a recently announced deal on pharmaceutical tariffs, which promises zero tariffs in exchange for the NHS increasing its costs, lacks any formal legal text beyond broad headline terms published in government press releases.

A Deal Without Detail

The arrangement concerning medicines, described as a "generational" achievement, remains an "agreement in principle" without a signed legal text. It has been highlighted that the public statements from the UK and US governments describe the deal in sharply different terms. The British version celebrates securing "duty-free access" as a singular success, while the American announcement highlights the expectation for the NHS to pay 25% more for new medications.

"We face a genuine possibility that the UK government has agreed to terms to raise drug prices in return for little more than a verbal promise from President Trump," said David Henig, a trade policy analyst. "It is documented he has form for not honouring his word."

Broader Instability and a Paused Tech Deal

Anxieties have been amplified by Washington's action to put on ice the major technology agreement, which was previously described as "a transformative pact" in the bilateral relationship. The US claimed a insufficient movement from the UK on reducing other tariffs as the reason for the pause.

In a separate development, concessions agreed to for British farmers as part of an initial accord have not been formally signed off by the US, despite a imminent January deadline. "We have been informed that that the US has not finalized the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

Privately, ministers have expressed concerns that the government's US-UK accords are lacking substance. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another described the situation as the "current reality" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, a senior MP on the health committee, remarked: "Perhaps most shocking than the administration's tactics is the UK government's credulous faith that his administration is a trustworthy negotiator. The NHS is too precious to be gambled with."

Official Reassurances and Concrete Outcomes

Government figures have downplayed the possibility of the US reneging on the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been pushing for the agreement, seeking certainty on imports and pricing, making it more concrete than the paused tech deal.

Officials concede that volatility is inherent in dealing with the Trump administration. However, they maintain that the UK has achieved real benefits for businesses, such as reduced duties on automobiles compared to other nations. "The fact we have 25% steel tariffs, which is better than the rate for the rest of the world, is a solid gain," one official said.

However, delays have arisen in carrying out the broader trade deal. Promised access for British beef have not materialized, and the assurance to "remove tariffs on British steel and aluminium" has is still pending, with tariffs remaining at 25%.

Moving forward, the two sides have scheduled to restart talks on the suspended digital agreement in January, following what were described as "productive" meetings between UK and US officials in Washington.